MarketsandMarkets Blog

The United States drug discovery services market is a highly advanced and dominant ecosystem characterized by robust research and development investments and a strong presence of leading pharmaceutical and biotechnology companies. The landscape is rapidly evolving through the integration of artificial intelligence, machine learning, and high-throughput screening, which significantly enhance the efficiency...

The United States wound care market is a robust and expanding sector of the healthcare industry, driven by an aging population and a significant rise in chronic conditions such as diabetes, obesity, and cardiovascular diseases. The landscape is characterized by a high prevalence of chronic wounds, including diabetic foot ulcers and pressure ulcers, which necessitate specialized and long-term care....

The United States next-generation sequencing market is a highly dynamic and mature ecosystem that serves as a global hub for genomic innovation and clinical integration. The landscape is defined by a robust infrastructure of leading biotechnology firms, prestigious academic research institutions, and advanced clinical laboratories that have transitioned sequencing technologies from niche research tools...

The United States GLP-1 analogues market is a rapidly expanding sector of the pharmaceutical industry, driven by an unprecedented surge in demand for effective treatments for type 2 diabetes and obesity. The landscape is characterized by a significant shift toward chronic weight management, supported by expanding FDA approvals and robust clinical evidence of cardiovascular benefits. While the market...

The United States medical device contract manufacturing market is a robust and rapidly expanding sector, driven by a strong domestic medtech industry and a growing reliance on specialized partners to manage the increasing complexity of medical technologies. The landscape is characterized by a strategic shift from transactional outsourcing to long-term end-to-end partnerships, where original equipment...

The United States active pharmaceutical ingredient market is a highly sophisticated and mature ecosystem defined by intense research and development and a robust regulatory framework overseen by the FDA. The landscape is characterized by a significant presence of multinational pharmaceutical giants, domestic manufacturers, and specialized contract development and manufacturing organizations that increasingly...

The United States contract research organization services market is a mature yet rapidly expanding sector characterized by a shift from traditional service-provider relationships toward AI-driven strategic partnerships. As the global leader in clinical development, the U.S. landscape is defined by a robust infrastructure and a heavy focus on high-value areas such as oncology, gene therapies, and rare...

The United States pharmaceutical contract manufacturing market is a highly competitive and concentrated landscape experiencing significant growth driven by a shift toward outsourcing to reduce capital expenditures and improve operational efficiency. The industry is currently defined by a transition phase where capacity expansions in sterile fill-finish suites and high-potency API manufacturing are...

The United States in vitro diagnostics market is a rapidly evolving sector driven by an aging population and a rising prevalence of chronic conditions like diabetes, cancer, and cardiovascular diseases. The landscape is characterized by a significant shift toward personalized medicine and the increasing adoption of point-of-care and home-based testing, which were further accelerated by the COVID-19...

The global clinical mass spectrometry market is undergoing a significant transformation as healthcare providers and diagnostic laboratories increasingly adopt high-precision analytical technologies to support advanced clinical testing. Valued at USD 1.75 billion in 2024, the market reached USD 1.92 billion in 2025 and is projected to grow to USD 3.31 billion by 2031, registering a robust CAGR of 9.5%...